Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Selling, General & Admin	13.95	11.16	12.16	13.14	9.15
Research & Development	36.81	39.42	40.88	34.52	28.31
Operating Expenses	50.76	50.59	53.05	47.66	37.46
Operating Income	-50.76	-50.59	-53.05	-47.66	-37.46
Interest & Investment Income	4.68	7.32	6.52	0.95	0.03
Currency Exchange Gain (Loss)	-0.33	0.19	-0.04	-0.9	-0.27
Other Non Operating Income (Expenses)	0.04	0.08	-0.94	-	0.05
EBT Excluding Unusual Items	-46.38	-43	-47.51	-47.62	-37.64
Pretax Income	-46.38	-43	-47.51	-47.62	-37.64
Income Tax Expense	-	-	-	0.36	0.27
Net Income	-46.38	-43	-47.51	-47.98	-37.91
Net Income to Common	-46.38	-43	-47.51	-47.98	-37.91
Shares Outstanding (Basic)	85	83	80	77	70
Shares Outstanding (Diluted)	85	83	80	77	70
Shares Change (YoY)	2.18%	4.61%	3.74%	10.18%	19.95%
EPS (Basic)	-0.54	-0.52	-0.60	-0.62	-0.54
EPS (Diluted)	-0.54	-0.52	-0.60	-0.62	-0.54
EBIT	-50.76	-50.59	-53.05	-47.66	-37.46

Updated Nov 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q